Phase 3 and Extensional Study of Besifovir

A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks

To prove that a study drug is noninferior to a control drug with a proportion of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week after 48-week administration of Besifovir 150 mg, or Tenofovir 300 mg as a control drug to chronic hepatitis B patients

Study Overview

• Status: Active, not recruiting
• Conditions: Chronic Hepatitis B
• Intervention / Treatment: Drug: besifovir 150mg; Drug: tenofovir 300mg

Detailed Description

• Screening Period Subject registration is conducted with confirming selection and exclusion criteria after a written consent form is obtained within 28 days before clinical trial drug administration.
• Wash-out Period Subjects who had been treated with antiviral agents within 12 weeks should complete a 4-week wash-out period from the stage of stopping antiviral agent treatment before a baseline visit and subjects who have no experience of antiviral agent treatment start a baseline visit without a wash-out period.
• Baseline Subjects who visit on the date of starting clinical trial drug administration are randomized to a test group or a control group at a ratio of 1:1. Double blindness is applied for both groups.
• Treatment period Subjects are orally administered with a clinical trial drug q.ds.i.d. for 48 weeks and visit at the 0, 4th, 12th, 24th, 36th, and 48th week for an HBV DNA test, laboratory tests, a physical test, vital signs, and adverse events.
• Follow-up period Subjects are provided with appropriate treatment after completing the 48-week trial or dropping out. Subjects visit once at the 60th week for follow-up of adverse events, such as acute deterioration of hepatitis B, and HBV DNA test results. If any treatment is not conducted after 48-week administration, subjects visit at intervals of four weeks until a follow-up visit (60th week) and the same tests with the 24th week visit (Visit 5) are conducted. However, subjects who participate in a 48-week separate extended trial conducted after 48-week administration in this clinical trial do not have a follow-up period.

• Study Type: Interventional
• Enrollment (Actual): 197
• Phase: Phase 3

Contacts and Locations

Study Locations

• Korea, Republic of
  • Daegu, Korea, Republic of
    • Kyungpook National University Hospital
  • Daejeon, Korea, Republic of
    • Chungnam National University Hospital
  • Incheon, Korea, Republic of
    • Inha University Hospital
  • Pusan, Korea, Republic of
    • Inje University Busan Paik Hospital
  • Seoul, Korea, Republic of
    • Seoul National University Hospital
  • Seoul, Korea, Republic of
    • Asan Medical Center
  • Seoul, Korea, Republic of
    • Gangnam Severance Hospital
  • Seoul, Korea, Republic of
    • The Catholic University of Korea, Seoul St. Mary's Hospital
  • Seoul, Korea, Republic of
    • Korea University Medical Center
  • Seoul, Korea, Republic of
    • Seoul National University Boramae Medical Center
  • Seoul, Korea, Republic of
    • Severance Hospital of Yonsei University
  • Seoul, Korea, Republic of
    • Soonchunhyang University Hospital
  • Seoul, Korea, Republic of
    • The Catholic University of Korea, Seoul St. Vincent's Hospital
  • Ulsan, Korea, Republic of
    • Ulsan University Hospital,
  • Chungchoengnam-do
    • Cheonan, Chungchoengnam-do, Korea, Republic of
      • Soonchunhyang University Hospital
  • Kangwon-do
    • ChunCheon, Kangwon-do, Korea, Republic of
      • Hallym University Medical Center
    • Wonju, Kangwon-do, Korea, Republic of
      • Wonju Sevrerance Christian Hospital
  • Kyounggi-do
    • Ansan, Kyounggi-do, Korea, Republic of
      • Korea University Medical Center
  • Kyunggi-do
    • Guri, Kyunggi-do, Korea, Republic of
      • Hanyang University Guri Hospital
    • Suwon,, Kyunggi-do, Korea, Republic of
      • Ajou University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female patients over the age of 20 years old
2. Patients who show positive HBsAg or has a history of chronic hepatitis B for the last six months or more before screening
3. Patients who have not received interferon (including Pegylation formulation) to treat chronic hepatitis and antiviral agents for more than 12 weeks.
4. Patients who showed positive HBsAg during screening
5. Patients who showed HBV DNA measured by COBAS TaqManTM HBV Test more than 1x105 copies/mL (17,241 IU/mL) in case of positive HBeAg during screening, or who showed HBV DNA measured by COBAS TaqManTM HBV Test more than 1x104 copies/mL (1,724 IU/mL) in case of negative HBeAg
6. Patients who showed ALT more than 1.2 times, or less than 10 times of the upper limit in the normal range during screening
7. Patients who were explained about the purpose, methods and effects of the clinical trial and then, signed a written consent form.
8. Male and female patients of childbearing age who can use double contraception acknowledged* during a trial period * Double contraception acknowledged means combination of barrier contraception (condom, diaphragm, etc.) and other contraception (sterilization operation, intrauterine contraceptive device, oral contraceptive drug, other hormone delivery system, contraceptive cream, jelly or foam, etc.).

Exclusion Criteria:

1. Patients who have hepatitis C (HCV), hepatitis D (HDV), or human immunodeficiency virus (HIV)

2. Patients with a uncompensated liver disease who have at least one of the following values or signs during screening

   • Total bilirubin > 2 x ULN
   • Prothrombin time delayed more than three seconds compared to the normal value
   • Serum Albumin < 30 g/L (3 g/dL)
   • A medical history of ascites, jaundice, hemorrhage by varix, hepatic encephalopathy, or other signs of liver function loss

3. At least one of the following laboratory values during screening

   • Hemoglobin < 9.0 g/dL
   • Absolute neutrophil count (ANC) < 1.5 x 109 /L (1500 /mm3)
   • Platelet count < 100 x 109 /L (100 x 103 /mm3)
   • Serum creatinine > 1.5 mg/dL
   • Serum amylase > 2 x ULN and Lipase > 2 x ULN
4. Patients who showed GFR less than 50 mL/min by calculating MDRD (Modification of Diet in Renal Disease: 1.86 x PCr -1.154 x AGE -0.203 (x 0.742 for women)) during screening
5. Patients who showed alpha-fetoprotein(AFP) more than 50 ng/mL during screening and are estimated to have hepatocellular carcinoma (HCC) through liver/abdomen CT scans

6. Patients who had received the following drugs for the last two months before screening (however, short-term use (less than consecutive 14 days) of these drugs and low-dose aspirin (100 mg, maximally, 300 mg/day) are allowed.)

   • Nephrotoxic drugs (e.g. Aminoglycosides, Amphotericin B, NSAIDs)
   • Hepatotoxic drugs (e.g. Erythromycin, Ketoconazole, Rifampin, Fluconazole, Dapsone)
   • Anticoagulant (e.g. Warfarin)
7. Patients who are suspected by an investigator to have the level of immunity decreased among patients who had been administered with immunosuppressants within six months before screening

8. Patients who had been administered with long-term general corticosteroids (more than consecutive 14 days) at a high dose (more than prednisolone 20 mg daily*) within three months before screening (In case of local corticosteroids, an investigator decides it.)

   * It is equal to cortisone 125 mg, hydrocortisone 100 mg, prednisone 20 mg, methylprednisolone 16 mg, triamcinolone 16 mg, dexamethasone 3 mg, betamethasone 2.4 mg.

9. Patients who were diagnosed as a malignant tumor within five years before screening or have a relapse of a malignant tumor (In case of a benign tumor, if an investigator decides that it does not affect the progress of the clinical trial during a trial period, the patients can be registered.)
10. Patients who are scheduled to participate in other clinical trial after registered in this clinical trial, or had been participated in other clinical trial within three months before registered in this clinical trial
11. Pregnant women, lactating women, or patients who planned pregnancy during a trial period
12. Patients who have hypersensitivity to the clinical trial drug in this clinical trial
13. Patients who have a past medical history of clinical alcohol or drug abuse within a year before screening or now are abusers
14. Patients who have a severe disease, such as liver diseases, heart failure, renal failure, and pancreatitis, decided by an investigator to have an effect on this clinical trial
15. Patients who have other hepatic diseases (hematochromatosis, Wilson's disease, alcoholic liver diseases, nonalcoholic steatohepatitis, α1-antitrypsin deficiency) except hepatitis B
16. Patients who received an organ transplant
17. Persons who are possible to decline daily function due to a mental disease or patients who are not able to understand the purpose and methods of this clinical trial
18. Patients who are decided by an investigator as unsuitable for conducting this clinical trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: besifovir 150mg; Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.	Drug: besifovir 150mg; Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Active Comparator: Tenofovir 300mg; Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.	Drug: tenofovir 300mg; Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week	The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) at the 48th week	at the 48th week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The rate of subjects who showed HBV DNA less than 116 copies/mL (20 IU/mL, LOQ of COBAS TaqManTM) at the 48th week	The rate of subjects who showed HBV DNA less than 116 copies/mL (20 IU/mL, LOQ of COBAS TaqManTM) at the 48th week	at the 48th week
Average amount of change in an HBV DNA common logarithm value at the 48th week to a base value	Average amount of change in an HBV DNA common logarithm value at the 48th week to a base value	at the 48th week
The rate of subjects who showed ALT normalized at the 48th week	The rate of subjects who showed ALT normalized at the 48th week	at the 48th week
The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) and ALT normalized at the 48th week	The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) and ALT normalized at the 48th week	at the 48th week
The rate of subjects who showed HBsAg serum loss and/or seroconversion (HBsAg loss and Anti-HBs formation) at the 48th week	The rate of subjects who showed HBsAg serum loss and/or seroconversion (HBsAg loss and Anti-HBs formation) at the 48th week	at the 48th week
The rate of subjects who showed HBeAg serum loss and/or seroconversion (HBeAg loss and Anti-HBe formation) at the 48th week among subjects with positive HBeAg	The rate of subjects who showed HBeAg serum loss and/or seroconversion (HBeAg loss and Anti-HBe formation) at the 48th week among subjects with positive HBeAg	at the 48th week
The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) and HBeAg loss at the 48th week among subjects with positive HBeAg	The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) and HBeAg loss at the 48th week among subjects with positive HBeAg	at the 48th week
The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) and HBeAg seroconversion at the 48th week among subjects with positive HBeAg	The rate of subjects who showed HBV DNA undetected (less than 400 copies/mL (69 IU/mL)) and HBeAg seroconversion at the 48th week among subjects with positive HBeAg	at the 48th week
Changes in antiviral drug resistant mutation according to HBV DNA sequencing results at the 48th week	Changes in antiviral drug resistant mutation according to HBV DNA sequencing results at the 48th week	at the 48th week
The rate of subjects who showed virologic breakthrough according to serum HBV DNA at the 48th week	The rate of subjects who showed virologic breakthrough according to serum HBV DNA at the 48th week	at the 48th week

Collaborators and Investigators

• Sponsor: IlDong Pharmaceutical Co Ltd
• Investigators: Principal Investigator: Kwan Sik Lee, M.d., Ph.D, Kangnam Severance Hospital, Yonsei University, Seoul, Korea; Principal Investigator: Young Oh Kweon, M.D., Ph.D, Kyungpook National University Hospital, Seoul, Korea; Principal Investigator: Hyung Joon Yim, M.D., Ph.D., Korea University Medical Center, Ansan, Kyunggi-do, Korea; Principal Investigator: Soon Ho Um, M.D., Ph.D., Korea University Medical Center, Seoul, Korea; Principal Investigator: Won Kim, M.D., Ph.D., Seoul National University Boramae medical Center, Seoul, Korea; Principal Investigator: Sung Jae Park, M.D., Ph.D., Inje University Busan Paik Hospital, Pusan, Korea; Principal Investigator: Yoon Jun Kim, M.D., Ph.D., Seoul National University Hospital, Seoul, Korea; Principal Investigator: Yoon Jun Kim, M.D., Ph.D., The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea; Principal Investigator: Young-Suk Lim, M.D., Ph.D., Asan medical center, Seoul, Korea; Principal Investigator: JinMo Yang, M.D., Ph.D., The Catholic University of Korea, Seoul St. Vincent's Hospital, Seoul, Korea; Principal Investigator: Jang, Jae Young, M.D., Ph.D., Soonchunhyang University Hospital, Seoul, Korea; Principal Investigator: Jae-Youn Cheong, M.D., Ph.D., Ajou University Medical Center, Suwon, Kyunggi-do, Korea; Principal Investigator: Neung Hwa Park, M.D., Ph.D., Ulsan University Hospital, Ulsan, Korea; Principal Investigator: Moon Young Kim, M.D., Ph.D., Wonju Sevrerance Christian Hospital, Wonju, Kangwon-do, Korea; Principal Investigator: Jin-Woo Lee, M.D., Ph.D., Inha University Hospital, Incheon, Inchen, Korea; Principal Investigator: Dong Joon Kim, M.D., Ph.D., Hallym University Medical Center, ChunCheon, Kangwon-do, Korea; Principal Investigator: Byung Seok Lee, M.D., Ph.D., Chungnam National University Hospital; Principal Investigator: Joo Hyun Sohn, M.D., Ph.D., Hanyang University Guri Hospital, Guri, Kyunggi-do, Korea; Principal Investigator: Kwang-Hyub Han, M.D., Ph.D., Severance Hospital of Yonsei University, Seoul, Korea; Principal Investigator: Hong Soo Kim, M.D., Ph.D., Soonchunhyang University Hospital, Choenan, Chungchoengnam-do, Korea

Publications and helpful links

General Publications

• Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Yang JM, Kim KH, Han KH, Um SH. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. Clin Mol Hepatol. 2021 Apr;27(2):346-359. doi: 10.3350/cmh.2020.0307. Epub 2021 Jan 25.
• Yim HJ, Kim W, Ahn SH, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Han KH. Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. Am J Gastroenterol. 2020 Aug;115(8):1217-1225. doi: 10.14309/ajg.0000000000000605.
• Ahn SH, Kim W, Jung YK, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Yim HJ, Lee KS, Lim YS, Lee WS, Park NH, Jin SY, Kim KH, Choi W, Han KH. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1850-1859.e4. doi: 10.1016/j.cgh.2018.11.001. Epub 2018 Nov 15.

Study record dates

Study Major Dates

• Study Start: October 1, 2013
• Primary Completion (Actual): February 1, 2016
• Study Completion (Anticipated): January 1, 2023

Study Registration Dates

• First Submitted: September 4, 2013
• First Submitted That Met QC Criteria: September 4, 2013
• First Posted (Estimate): September 10, 2013

Study Record Updates

• Last Update Posted (Actual): January 27, 2020
• Last Update Submitted That Met QC Criteria: January 23, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Keywords: Chronic hepatitis B
• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Enterovirus Infections; Picornaviridae Infections; Hepatitis B; Hepatitis; Hepatitis A; Hepatitis B, Chronic; Hepatitis, Chronic; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Tenofovir
• Other Study ID Numbers: ID_BVCL011